34 results about "Intravenous route" patented technology

The invention relates to the field of nanometer drug carriers, and concretely relates to an asymmetric magnetic mesoporous silica rod supporting chemotherapeutic and gene drugs and application thereof to tumor diagnosis and treatment. The asymmetric magnetic mesoporous silica rod is prepared by employing spherical magnetic ferrite nanoparticles and ethyl orthosilicate through a sol-gel method, and the asymmetric magnetic mesoporous silica rod is subjected to surface functionalization modification, and is successively loaded with a chemotherapeutic drug, coated by a positive high-molecular polymer and loaded with a gene drug, so that a target product is obtained. The chemotherapeutic drug is connected with the silica rod through functionalization of the mesoporous surface, and the silica rod is endowed with the pH-responsive drug release characteristic, also the biocompatibility of the composite material is increased and the in-vivo cycling time is prolonged, and gene is supported in an electrostatic adsorption mode. The composite material is injected into a living body via an intravenous route, the characteristics of nanoparticle in-vivo passive targeting, gene guiding and pH-responsive drug release of the composite material are utilized, also the cooperativity of the multidrug resistant gene and the chemotherapeutic drug is utilized, and in-vitro magnetic targeting, NMR imaging and other technologies are applied to diagnosis and treatment of malignant tumors.

The invention relates to an NRP-1 ligand polypeptide-polyethylene glycol-phosphatide compound, an active targeting liposome drug delivery system mediated thereby and a preparation method thereof. A carrier system comprises; a. phosphatide; b. cholesterol; c. methoxy polyethylene glycol-phosphatide compound; and d. polypeptide-polyethylene glycol-phosphatide compound containing an RPARPAR sequence. The above components are in a molar ratio of: a:b=5:1-1:5, a:c=1000:0.1-1000:100, and a:d=1000:0.1-1000:100. The system can carry out intravenous route drug administration and target the drug to a tumour position according to tumour EPR effect and RPARPAR mediation effect. The liposome drug delivery system can be applied to tumour diagnosis or targeting delivery of a treatment medicament.

The present invention provides injectable formulations of water-soluble salts of diclofenac in single doses of less than 2 ml, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route. More specifically the injectable preparations contain 75 mg to 100 mg of water-soluble salts of diclofenac, in about 1 ml injection solution without significantly raising the viscosity of the injection solution without the use surfactants. The formulations are adjusted to pH 6 to 10 containing up to 100 mg of diclofenac salt in a medium comprising of water, along with one or more co-solvent(s)/solubiliser(s), antioxidants, preservatives, buffers, alkali and stabilizers.

The invention discloses a needle component which comprises a transparent or semi-transparent shell. The shell comprises a fluid inlet end portion, a fluid outlet end portion, a flashing flow cavity and an aerating mechanism. The aerating mechanism is arranged among the fluid inlet end portion, the fluid outlet end portion and the flashing flow cavity. An inlet sleeve and an outlet sleeve which are approximately axially aligned extend from the shell and are communicated with the cavity. A sealable sleeve covers the outer end portion of the outlet sleeve. The relative volumes of the sleeves, the cavity and the sealable sleeve are selected to provide rapid and reliable flashing flow indications for intravenous routes. An internal aerating element is positioned in the shell to enable the inner portion to be divided into a first cavity and a second cavity. The second cavity is suitable for keeping negative pressure inside relative to an external environment so as to prevent blood from leaking from a needle when the needle is withdrawn from a patient.

The present disclosure relates to the treatment of agitation or signs of agitation in certain human subjects, including subjects with a neurodegenerative, neuropsychiatric or opioid withdrawal disorder, by administering dexmedetomidine hydrochloride by the intravenous route.

The present invention relates a composition comprising Diclofenac and salts thereof wherein Diclofenac or its salts are present in an amount of 25-200 mg. The composition is suitable for the parenteral administration through intramuscular, intravenous route; also for oral, dermal, subcutaneous, cutaneous, nasal, ocular drops, as rectal suppository, vaginal pessaries, intra-articular, and otic delivery. The invention also provides compositions comprising a combination of Diclofenac and other drugs. The invention further provides a method for preparing said composition.

The present invention discloses chonsurid preparation capable of being used for venous injection and its preparation process. The purified chonsurid preparation may be used for intramuscular injection and intravenous injection after being added into glucose solution or physiological saline, and has convenient use. Owing to the raised purity of chonsurid, the chonsurid preparation may be injected directly into blood circulation system resulting in high blood medicine concentration, fast acting, high curative effect and less side effect.

The invention provides a [dichloro-1,2-cyclohexanediamine]platinum complex, and the complex is obtained from the complex reactions between dichloro-1,2-cyclohexanediamine and a polymer which has the structure of the formula (I). The [Dichloro-1,2-cyclohexanediamine]platinum has a cyclohexanediamine structure, a stable inner-core structure is formed because of the accumulation and hydrophobic effect after the [Dichloro-1,2-cyclohexanediamine]platinum cooperate with a polymer, and the stability of the [Dichloro-1,2-cyclohexanediamine]platinum is good under physiology conditions. The complex can effectively avoid the problems of sudden release and non-specific interaction of [Dichloro-1,2-cyclohexanediamine]platinum after [Dichloro-1,2-cyclohexanediamine]platinum enters the blood circulation system through intravenous route. The complex can be assembled to form a micelle structure; accumulation of the complex on the tumor locations can be achieved through strengthening osmotic and retention effects, and thus the goals of reducing toxic and by effects and improving curative effects are achieved. Furthermore, the adopted complex has a good biological compatibility, is capable of degrading in human bodies, and thus the prepared [Dichloro-1,2-cyclohexanediamine]platinum has a good solubility.

Disclosed herein are injectable compositions containing high concentration of paracetamol or its pharmaceutically acceptable salts wherein the concentration of paracetamol or its pharmaceutically acceptable salt is >150 mg/ml in a judiciously tailored solvent system comprising glycofurol, ethanol, water or a solvent system comprising glycofurol, ethanol, polyethylene glycol, water. The viscosity of the said injectables is <28 cps. Further disclosed is the process for preparing the said injectables. The injectables can be administered by intramuscular route, intravenous route or as intravenous infusion after diluting in one of the routinely used intravenous fluids, infusion solutions of antibacterial, antifungal and amoebicidal drugs and along with anxiolytics (Midazolam injection) or narcotic analgesics (Fentanyl Citrate injection etc) as they remain stable, clear and transparent at least for 6 hours after dilution.

The present invention disclosed methods for suppressing or preventing an immune response to a specific antigen in a subject, comprising administering to the subject, the specific antigen by an intravenous route followed by an inhalation route.

Injectable formulations of water-soluble salts of diclofenac, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route.

The present invention relates to the field of treating an individual at risk of cardiovascular adverse events with an intravenous iron carbohydrate complex, such as iron isomaltoside, where treatment of iron deficiency reduces the incidence or risk of cardiovascular adverse events in the individual. In another aspect, the present invention provides a method of reducing P-wave dispersion/time limit for treating an animal having atrial fibrillation or a disease associated with atrial fibrillation (e.g., heart failure, hypertension, heart valvular disease, coronary heart disease, obesity, and diabetes), the method comprises administering a therapeutically effective amount of an iron agent to the animal by oral, intramuscular or intravenous route.

Conventional injectable formulations of Diclofenac are known to have excipients which cause irritation at the site of injection and are painful. Further, such conventional formulations also cause thrombophlebitis. Other injectable formulations of Diclofenac known in the prior art also contain excipients which are tissue irritants and may cause toxicity when administered through intravenous route. The cyclodextrin compounds used in Dyloject® may cause problems while elimination in the renal compromised patients. The present invention therefore provides injectable Diclofenac formulations which do not cause irritation and pain at the site of injection. Further, the formulations of the present invention do not include cyclodextrins, therefore can also be administered to the renal compromised patients.

The invention discloses an intravenous nutrition formula for newborns, which is prepared from water levistat, 10% of NaCl, 15% of NaCl, Grifors, 20% of fat emulsion, 6% of pediatric compound amino acid, 10% of GS, 50% of GS, Vitalipiride, Andamex and levocarnitine. The intravenous nutrition formula is suitable for newborns which cannot be fed by mouth or are partially fed by mouth, the insufficient part of newborns are fed by vein, various daily required nutrient substances are input through an intravenous way, and the traditional Chinese medicine is free of toxic and side effects, quick in effect, simple and easy to implement.

A method for treating a cancer by administering a therapeutically active composition for the treatment in a patient or human thereof, is disclosed. The method according to the present invention, comprises a step of administering to the human a pharmaceutical composition comprising a therapeutic amount of sodium thiosulfate (Na₂S₂O₃) along with at least one of a pharmaceutical carrier and a pharmaceutical excipient. The carriers, or excipients are selected corresponding to the mode of administration to the patient with cancer includes gastric cancer, fibrosarcoma, pancreatic cancer, and head and neck carcinomas. The method further comprises a step of administering the said composition is any one of oral route, intravenous route, inhalation route, intra-vesical route, vaginal route, rectal route, sublingual route, ophthalmic route and topical route.